Free Trial

Jyong Biotech (NASDAQ:MENS) Shares Gap Up - What's Next?

Jyong Biotech logo with Manufacturing background

Key Points

  • Jyong Biotech's shares opened at $54.00 after previously closing at $51.82, reflecting significant investor interest as the stock last traded at $56.00.
  • Wall Street analysts upgraded Jyong Biotech to a "hold" rating, which may influence future market performance and investor decisions.
  • The company's 50-day moving average is currently at $34.25, indicating a positive upward trend in stock performance.
  • Five stocks to consider instead of Jyong Biotech.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $51.82, but opened at $54.00. Jyong Biotech shares last traded at $56.00, with a volume of 4,582 shares.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a report on Monday, June 30th.

Check Out Our Latest Report on MENS

Jyong Biotech Price Performance

The firm's fifty day simple moving average is $38.03.

Jyong Biotech Company Profile

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

See Also

Should You Invest $1,000 in Jyong Biotech Right Now?

Before you consider Jyong Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.

While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.